{"clinical_study": {"@rank": "203", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 06, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04327570"}, "id_info": {"org_study_id": "COntAGIouS", "nct_id": "NCT04327570"}, "brief_title": "In-depth Immunological Investigation of COVID-19.", "acronym": "COntAGIouS", "official_title": "In-depth Characterisation of the Dynamic Host Immune Response to Coronavirus SARS-CoV-2", "sponsors": {"lead_sponsor": {"agency": "Universitaire Ziekenhuizen Leuven", "agency_class": "Other"}}, "source": "Universitaire Ziekenhuizen Leuven", "oversight_info": {"has_dmc": "No", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "The COntAGIouS trial (COvid-19 Advanced Genetic and Immunologic Sampling; an in-depth\n      characterization of the dynamic host immune response to coronavirus SARS-CoV-2) proposes a\n      transdisciplinary approach to identify host factors resulting in hyper-susceptibility to\n      SARS-CoV-2 infection, which is urgently needed for directed medical interventions."}, "detailed_description": {"textblock": "The overall aim of this prospective study is to provide an in-depth characterization of\n      clinical and immunological features of patients hospitalized in UZ Leuven because of\n      SARS-CoV-2 infection. For this purpose, clinical data and blood, nasopharyngeal/rectal swab,\n      and if safe, bronchoalveolar lavage (BAL) fluid and lung tissue samples will be collected\n      from PCR- or CT-confirmed COVID-19 patients, with varying degrees of disease severity.\n      Assessed characteristics will be compared between severe and non-severe COVID-19 patients,\n      and between COVID-19 positive and negative ('control') patients."}, "overall_status": "Not yet recruiting", "start_date": {"@type": "Anticipated", "#text": "March 27, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "September 30, 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "September 30, 2020"}, "study_type": "Observational [Patient Registry]", "has_expanded_access": "No", "study_design_info": {"observational_model": "Other", "time_perspective": "Prospective"}, "target_duration": "6 Months", "primary_outcome": [{"measure": "Clinical Features", "time_frame": "6 months", "description": "Description of clinical, laboratory and radiological features of illness and complications."}, {"measure": "Immune host response at systemic level", "time_frame": "6 months", "description": "Evaluation of dynamic host immune response at systemic level (immune signalling molecules in plasma, peripheral blood mononuclear cell isolation for advanced immunophenotyping and transcriptomics). Real-time analysis using CyTOF will be performed as screening, in combination with in-depth immunophenotyping."}, {"measure": "Immune host response at local level", "time_frame": "6 months", "description": "Evaluation of dynamic host immune response at systemic level (immune signalling molecules in plasma, peripheral blood mononuclear cell isolation for advanced immunophenotyping and transcriptomics)."}, {"measure": "Host genetic variation", "time_frame": "6 months", "description": "Identification of host genetic variants that are associated with severity of disease."}], "secondary_outcome": [{"measure": "Comparison severe and non-severe COVID-19 hospitalised patients", "time_frame": "6 months", "description": "Differences in baseline factors"}, {"measure": "Comparison severe and non-severe COVID-19 hospitalised patients", "time_frame": "6 months", "description": "Differences in immune characteristics"}, {"measure": "Correlation of findings with outcome", "time_frame": "6 months", "description": "Correlation of findings with outcome, aiming to identify early biomarkers of severe disease and putative targets for immunomodulatory therapy"}, {"measure": "Correlation of immune profiling - microbiome", "time_frame": "6 months", "description": "Correlation of immune profiling with microbiome analysis of patients"}], "number_of_groups": "2", "enrollment": {"@type": "Anticipated", "#text": "100"}, "condition": "Coronavirus Infections", "arm_group": [{"arm_group_label": "ICU-hospitalised COVID-19 patients", "description": "COVID-19 positive patients hospitalised in intensive care ('severe disease')."}, {"arm_group_label": "ward-hospitalised COVID-19 patients", "description": "COVID-19 positive patients requiring hospitalisation,not on intensive care department ('non-severe')."}], "intervention": {"intervention_type": "Other", "intervention_name": "Patient sampling", "description": "Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable", "arm_group_label": ["ICU-hospitalised COVID-19 patients", "ward-hospitalised COVID-19 patients"]}, "biospec_retention": "Samples With DNA", "biospec_descr": {"textblock": "Blood, plasma, PBMC, BAL, lung tissue"}, "eligibility": {"study_pop": {"textblock": "All non-immunosuppressed* consecutive patients (>18 years old) that are admitted to UZ\n        Leuven from March 2020 until September 2020 with PCR-confirmed and/or CT-confirmed\n        SARS-CoV-2 disease are eligible for inclusion."}, "sampling_method": "Non-Probability Sample", "criteria": {"textblock": "Inclusion Criteria:\n\n          -  Patients >/= 18 years old AND\n\n          -  Hospitalised with PCR-confirmed and/or CT-confirmed SARS-CoV-2 disease\n\n        Exclusion Criteria:\n\n          -  Age < 18 years old\n\n          -  No informed consent\n\n          -  Patients on cyclosporine/tacrolimus/sirolimus/everolimus therapy*"}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No"}, "overall_official": {"last_name": "Joost Wauters, MD PhD", "role": "Principal Investigator", "affiliation": "UZ Leuven"}, "overall_contact": {"last_name": "Joost Wauters, MD PhD", "phone": "003216344275", "email": "joost.wauters@uzleuven.com"}, "verification_date": "March 2020", "study_first_submitted": "March 26, 2020", "study_first_submitted_qc": "March 26, 2020", "study_first_posted": {"@type": "Actual", "#text": "March 31, 2020"}, "last_update_submitted": "March 26, 2020", "last_update_submitted_qc": "March 26, 2020", "last_update_posted": {"@type": "Actual", "#text": "March 31, 2020"}, "responsible_party": {"responsible_party_type": "Sponsor"}, "keyword": "COVID-19", "condition_browse": {"mesh_term": ["Coronavirus Infections", "Severe Acute Respiratory Syndrome"]}, "patient_data": {"sharing_ipd": "Undecided"}}}